SOURCE: SNN Incorporated

SNN Incorporated

June 25, 2015 08:30 ET Publishes New SNNLive Video Interview With Immune Pharmaceuticals, Inc.

LOS ANGELES, CA--(Marketwired - Jun 25, 2015) -, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), applies a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted, monoclonal antibody therapeutics, according to the company's website (see here: The video interview was recorded at the Marcum MicroCap Conference on May 28th, 2015 in New York City, NY.

Click the following link to watch the SNNLive Video Interview on

Mid-Year Review 2015 with Immune Pharmaceuticals, Inc. - Developing Therapeutics to Combat Crohn's Disease and Colitis


Please review important disclosures on our website at:

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of AstraZeneca. Immune also signed a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical topical nano-formulated cyclosporin A for the treatment of psoriasis and atopic dermatitis, according the company's most recent press release (see here: Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for Phase III. AmiKet has received Orphan Drug Designation for Post-Herpetic Neuralgia. Company description and for more information, go to:

About is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on

Contact Information